Other news to note
Retrophin Inc., of New York, said it submitted a proposal to the board of Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for 0.175 Retrophin shares per Clinuvel share, or A$2.17 (US$2.04) per share in cash.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST